Literature DB >> 21600537

Usefulness of plasma galectin-3 levels in systolic heart failure to predict renal insufficiency and survival.

W H Wilson Tang1, Kevin Shrestha, Zhili Shao, Allen G Borowski, Richard W Troughton, James D Thomas, Allan L Klein.   

Abstract

Galectin-3 plays an important role in fibroblast activation and fibrosis in animal models. Increased galectin-3 levels are associated with poor long-term survival in heart failure (HF). We examined the relation between plasma galectin-3 levels and myocardial indexes of systolic HF. We measured plasma galectin-3 in 133 subjects with chronic HF and 45 with advanced decompensated HF using echocardiographic and hemodynamic evaluations. In the chronic HF cohort, median plasma galectin-3 level was 13.9 ng/ml (interquartile range 12.1 to 16.9). Higher galectin-3 was associated with more advanced age (r = 0.22, p = 0.010), poor renal function (estimated glomerular filtration rate, r = -0.24, p = 0.007; cystatin C, r = 0.38, p <0.0001) and predicted all-cause mortality (hazard ratio 1.86, 95% confidence interval 1.36 to 2.54, p <0.001). In multivariate analysis, galectin-3 remained an independent predictor of all-cause mortality after adjusting for age, estimated glomerular filtration rate, left ventricular (LV) ejection fraction, and mitral early diastolic myocardial relaxation velocity at septal mitral annulus (hazard ratio 1.94, 95% confidence interval 1.30 to 2.91, p = 0.001). However, galectin-3 did not predict the combined end point of all-cause mortality, cardiac transplantation, or HF hospitalization (p >0.05). Furthermore, there were no relations between galectin-3 and LV end-diastolic volume index (r = -0.05, p = 0.61), LV ejection fraction (r = 0.10, p = 0.25), or LV diastolic function (mitral early diastolic myocardial relaxation velocity at septal mitral annulus, r = 0.06, p = 0.52; left atrial volume index, r = 0.08, p = 0.41). In the advanced decompensated HF cohort, we did not observe any relation between galectin-3 and echocardiographic or hemodynamic indexes. In conclusion, high plasma galectin-3 levels were associated with renal insufficiency and poorer survival in patients with chronic systolic HF. However, we did not observe a relation between galectin-3 and echocardiographic or hemodynamic indexes.
Copyright © 2011 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21600537      PMCID: PMC3137764          DOI: 10.1016/j.amjcard.2011.03.056

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  22 in total

1.  Utility of amino-terminal pro-brain natriuretic peptide, galectin-3, and apelin for the evaluation of patients with acute heart failure.

Authors:  Roland R van Kimmenade; James L Januzzi; Patrick T Ellinor; Umesh C Sharma; Jaap A Bakker; Adrian F Low; Abelardo Martinez; Harry J Crijns; Calum A MacRae; Paul P Menheere; Yigal M Pinto
Journal:  J Am Coll Cardiol       Date:  2006-08-28       Impact factor: 24.094

2.  Recommendations for chamber quantification: a report from the American Society of Echocardiography's Guidelines and Standards Committee and the Chamber Quantification Writing Group, developed in conjunction with the European Association of Echocardiography, a branch of the European Society of Cardiology.

Authors:  Roberto M Lang; Michelle Bierig; Richard B Devereux; Frank A Flachskampf; Elyse Foster; Patricia A Pellikka; Michael H Picard; Mary J Roman; James Seward; Jack S Shanewise; Scott D Solomon; Kirk T Spencer; Martin St John Sutton; William J Stewart
Journal:  J Am Soc Echocardiogr       Date:  2005-12       Impact factor: 5.251

Review 3.  Digesting the remodeled heart: role of lysosomal cysteine proteases in heart failure.

Authors:  Flora Sam; Deborah A Siwik
Journal:  Hypertension       Date:  2006-09-18       Impact factor: 10.190

4.  Cystatin C, left ventricular hypertrophy, and diastolic dysfunction: data from the Heart and Soul Study.

Authors:  Joachim H Ix; Michael G Shlipak; Glenn M Chertow; Sadia Ali; Nelson B Schiller; Mary A Whooley
Journal:  J Card Fail       Date:  2006-10       Impact factor: 5.712

5.  Galectin-3 modulates rat mesangial cell proliferation and matrix synthesis during experimental glomerulonephritis induced by anti-Thy1.1 antibodies.

Authors:  S Sasaki; Q Bao; R C Hughes
Journal:  J Pathol       Date:  1999-03       Impact factor: 7.996

6.  Usefulness of tissue doppler and color M-mode indexes of left ventricular diastolic function in predicting outcomes in systolic left ventricular heart failure (from the ADEPT study).

Authors:  Richard W Troughton; David L Prior; Christopher M Frampton; Patrick J Nash; Jeremy J Pereira; Maureen Martin; Annette Fogarty; Annitta J Morehead; Randall C Starling; James B Young; James D Thomas; Michael S Lauer; Allan L Klein
Journal:  Am J Cardiol       Date:  2005-07-15       Impact factor: 2.778

7.  Galectin-3 marks activated macrophages in failure-prone hypertrophied hearts and contributes to cardiac dysfunction.

Authors:  Umesh C Sharma; Saraswati Pokharel; Thomas J van Brakel; Jop H van Berlo; Jack P M Cleutjens; Blanche Schroen; Sabine André; Harry J G M Crijns; Hans-J Gabius; Jos Maessen; Yigal M Pinto
Journal:  Circulation       Date:  2004-11-01       Impact factor: 29.690

8.  Plasma B-type natriuretic peptide levels in systolic heart failure: importance of left ventricular diastolic function and right ventricular systolic function.

Authors:  Richard W Troughton; David L Prior; Jeremy J Pereira; Maureen Martin; Annette Fogarty; Annitta Morehead; Timothy G Yandle; A Mark Richards; Randall C Starling; James B Young; James D Thomas; Allan L Klein
Journal:  J Am Coll Cardiol       Date:  2004-02-04       Impact factor: 24.094

9.  Predictive value of plasma galectin-3 levels in heart failure with reduced and preserved ejection fraction.

Authors:  Rudolf A de Boer; Dirk J A Lok; Tiny Jaarsma; Peter van der Meer; Adriaan A Voors; Hans L Hillege; Dirk J van Veldhuisen
Journal:  Ann Med       Date:  2010-12-28       Impact factor: 4.709

10.  Galectin-3 regulates myofibroblast activation and hepatic fibrosis.

Authors:  Neil C Henderson; Alison C Mackinnon; Sarah L Farnworth; Francoise Poirier; Francesco P Russo; John P Iredale; Christopher Haslett; Kenneth J Simpson; Tariq Sethi
Journal:  Proc Natl Acad Sci U S A       Date:  2006-03-20       Impact factor: 11.205

View more
  67 in total

Review 1.  Clinical use of novel biomarkers in heart failure: towards personalized medicine.

Authors:  Daniela Schmitter; Gadi Cotter; Adriaan A Voors
Journal:  Heart Fail Rev       Date:  2014-05       Impact factor: 4.214

2.  Galectin-3 and new-onset CKD: marker or mediator?

Authors:  Pietro Ravani; Brendan J Barrett
Journal:  J Am Soc Nephrol       Date:  2013-06-20       Impact factor: 10.121

3.  Galectin-3 in ambulatory patients with heart failure: results from the HF-ACTION study.

Authors:  G Michael Felker; Mona Fiuzat; Linda K Shaw; Robert Clare; David J Whellan; Luca Bettari; Shailesh C Shirolkar; Mark Donahue; Dalane W Kitzman; Faiez Zannad; Ileana L Piña; Christopher M O'Connor
Journal:  Circ Heart Fail       Date:  2011-10-20       Impact factor: 8.790

Review 4.  Review of the prognostic value of galectin-3 in heart failure focusing on clinical utility of repeated testing.

Authors:  Francisco Javier Carrasco-Sánchez; María Inmaculada Páez-Rubio
Journal:  Mol Diagn Ther       Date:  2014-12       Impact factor: 4.074

Review 5.  The systemic nature of CKD.

Authors:  Carmine Zoccali; Raymond Vanholder; Ziad A Massy; Alberto Ortiz; Pantelis Sarafidis; Friedo W Dekker; Danilo Fliser; Denis Fouque; Gunnar H Heine; Kitty J Jager; Mehmet Kanbay; Francesca Mallamaci; Gianfranco Parati; Patrick Rossignol; Andrzej Wiecek; Gerard London
Journal:  Nat Rev Nephrol       Date:  2017-04-24       Impact factor: 28.314

Review 6.  Biomarkers to Predict Reverse Remodeling and Myocardial Recovery in Heart Failure.

Authors:  Shweta R Motiwala; Hanna K Gaggin
Journal:  Curr Heart Fail Rep       Date:  2016-10

7.  Galectin-3, Renal Function, and Clinical Outcomes: Results from the LURIC and 4D Studies.

Authors:  Christiane Drechsler; Graciela Delgado; Christoph Wanner; Katja Blouin; Stefan Pilz; Andreas Tomaschitz; Marcus E Kleber; Alexander Dressel; Christoph Willmes; Vera Krane; Bernhard K Krämer; Winfried März; Eberhard Ritz; Wiek H van Gilst; Pim van der Harst; Rudolf A de Boer
Journal:  J Am Soc Nephrol       Date:  2015-01-07       Impact factor: 10.121

Review 8.  Right Heart Failure and Cardiorenal Syndrome.

Authors:  Thida Tabucanon; Wai Hong Wilson Tang
Journal:  Cardiol Clin       Date:  2020-03-02       Impact factor: 2.213

9.  Left ventricular mass progression despite stable blood pressure and kidney function in stage 3 chronic kidney disease.

Authors:  Michael E Seifert; Lisa de Las Fuentes; Charles Ginsberg; Marcos Rothstein; Dennis J Dietzen; Steven C Cheng; Will Ross; David Windus; Victor G Dávila-Román; Keith A Hruska
Journal:  Am J Nephrol       Date:  2014-05-06       Impact factor: 3.754

10.  Prognostic Value of Galectin-3 for Adverse Outcomes in Chronic Heart Failure.

Authors:  Benjamin French; Le Wang; Bonnie Ky; Jeffrey Brandimarto; Anupam Basuray; James C Fang; Nancy K Sweitzer; Thomas P Cappola
Journal:  J Card Fail       Date:  2015-11-10       Impact factor: 5.712

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.